martes, 22 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Which Pharma Stock Stands Taller Right Now: LLY or PFE?

View original at finance.yahoo.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product portfolios and robust R&D engines…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lilly is a clear winner over Pfizer due to exceptional growth from Mounjaro and Zepbound, product and pipeline portfolio in high-growth therapeutic areas like obesity, robust growth prospects and bullish analyst sentiment

    80% confidence

  • Orforglipron has potential to be approved and launched in 2026

    80% confidence

  • COVID revenues expected to be around $5 billion in 2026, $1.5 billion less than expected sales of about $6.5 billion in 2025

    80% confidence

  • Pfizer's 2026 EPS expected to decline 4.2% year-over-year

    80% confidence

  • Lilly's 2026 sales expected to increase 22.6% year-over-year

    80% confidence

  • Mounjaro and Zepbound are expected to continue to see strong demand in 2026

    80% confidence

  • Metsera candidates expected to generate billions of dollars in peak sales

    80% confidence

  • New and acquired products expected to deliver double-digit growth in 2026

    80% confidence

  • Cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027

    80% confidence

  • Data readouts from three phase III studies on retatrutide for treating obesity expected in the second half of 2026

    80% confidence

  • Pfizer's 2026 sales expected to decline 2.1% year-over-year

    80% confidence

  • Lilly's 2026 EPS expected to increase 39.5% year-over-year

    80% confidence

  • Loss of exclusivity cliff expected to hurt sales by approximately $1.5 billion in 2026

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,983
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,983 hechos verificados con la fuente5,304 documentos fuente archivados
Consulta estos datos → isubstrate.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? — Source | Via News | es.VIA.NEWS